A review of the metabolic effects of sibutramine
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is associated with an increased incidence of diabetes, hypertension, dyslipidaemia and coronary artery disease. Current management strategies of obesity include lifestyle management strategies of obesity include lifestyle interventions and pharmaco therapy. Sibutramine is a drug with established efficacy in weight reduction and maintenance of weight loss. It reduces food intake and attenuates the fall in reduces food intake and attenuates the fall in metabolic rate associated with weight loss. OBJECTIVE: To review the metabolic effects associated with sibutramine use. METHODS: Relevant articles were identified through a Medline search (up to December 2004). RESULTS: Weight loss with sibutramine treatment is associated with improved insulin sensitivity and a fall in glycosylated haemoglobin levels in type 2 diabetic patients. In most trials sibutramine exerted favourable effects on lipids, especially exerted favourable effects on lipids, especially on high density lipoprotein (HDL) cholesterol and triglycerides, as well as on the total:HDL cholesterol ratio. Sibutramine also lowers serum uric acid concentrations. Furthermore, this drug seems to favourably influence adipocytokines; it reduces serum leptin and resistin levels and increases adiponectin levels. Sibutramine also exerts a beneficial effect on hyper androgenaemia in obese women with polycystic ovary syndrome. Preliminary findings also suggest that weight loss following treatment with sibutramine is useful in patients with non-alcoholic fatty liver disease (NAFLD). CONCLUSION: Weight loss following sibutramine administration is associated with several favourable metabolic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adipokines: inflammation and the pleiotropic role of white adipose tissue
Trayhurn, P., & Wood, I. S. (2004) · British Journal of Nutrition · doi:10.1079/bjn20041213 · Cited by 2,210
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817
Padwal, R., Li, S. K., & Lau, D. C. W. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802475 · Cited by 348
Fujioka, K., Seaton, T. B., Rowe, E., Jelinek, C. A., Raskin, P., Lebovitz, H. E., Weinstein, S. P., & Group, T. S. C. S. (2000) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00081.x · Cited by 244 · cited 2×
“Furthermore, Fujioka et al.24 determined the efficacy of sibutramine treatment for 6 months in obese patients whose type 2 diabetes was poorly controlled on diet alone or with an oral antidiabetic agent.”
BackgroundThe Epidemiology of Central Fat Distribution in Relation to Disease
Pi-Sunyer, F. X. (2004) · Nutrition Reviews · doi:10.1111/j.1753-4887.2004.tb00081.x · Cited by 153
Sabuncu, T., Harma, M., Harma, M., Nazligul, Y., & Kilic, F. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)02162-9 · Cited by 78
Kamel, E., McNeill, G., & Van Wijk, M. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801204 · Cited by 77 · cited 2×
“Furthermore, Kamel et al.44 estimated the changes in intra-abdominal adipose tissue measured by magnetic resonance imaging in patients receiving 10 mg/ day sibutramine and a low-calorie diet for 6 months and concluded that the percentage of changes in intraabdominal adipose tissue was greater than that in subcutaneous…”
BackgroundInfluentialDerosa, G., Cicero, A. F. G., Murdolo, G., Piccinni, M. N., Fogari, E., Bertone, G., Ciccarelli, L., & Fogari, R. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00372.x · Cited by 67
Cited by
Finding function in novel targets: C. elegans as a model organism
Kaletta, T., & Hengartner, M. O. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2031 · Cited by 1,093
The link between abdominal obesity, metabolic syndrome and cardiovascular disease
Ritchie, S. A., & Connell, J. M. C. (2007) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2006.07.005 · Cited by 726
Metabolic syndrome, diabetes, and hyperuricemia
Li, C., Hsieh, M.-C., & Chang, S.-J. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835d951e · Cited by 467
Orlistat-Associated Adverse Effects and Drug Interactions: A Critical Review
Filippatos, T. D., Derdemezis, C. S., Gazi, I. F., Nakou, E. S., Mikhailidis, D. P., & Elisaf, M. S. (2008) · Drug Safety · doi:10.2165/00002018-200831010-00005 · Cited by 434
Self-citationThe role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 277
Metadata
- Authors
- Filippatos, T. D., Kiortsis, D. N., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. S.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2005-03
- Volume
- 21
- Issue
- 3
- Pages
- 457-466
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2020794562
- Cited by
- 85
- References
- 11
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of the metabolic effects of sibutramine. https://app.cochat.ai/papers/10.1185/030079905x38132
- The paper
- Filippatos, T. D., Kiortsis, D. N., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. S. (2005). A review of the metabolic effects of sibutramine. Current Medical Research and Opinion. https://doi.org/10.1185/030079905x38132
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.